Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | AML: novel conditioning and maintenance strategies

Ravi Vij • 15 Sep 2019
IMW 2019
Acute Myeloid Leukemia Leukemia Multiple Myeloma Myelodysplastic Syndromes Azacitidine Busulfan

Ravi Vij, MD, MBA Washington University Medical School, St Louis, MO, outlines novel conditioning therapies and maintenance strategies for acute myeloid leukemia (AML) and myelodysplastic syndrome at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Ravi Vij

2:48
MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma
Ravi Vij • 11 Dec 2023
2:26
Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma
Ravi Vij • 11 Dec 2023
3:23
Updated safety and efficacy results of Abbv-383, a novel BsAb, in patients with R/R multiple myeloma
Ravi Vij • 11 Dec 2023
2:35
Resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
Ravi Vij • 12 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals